PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery
by: M. Untch, P. A. Fasching, G. E. Konecny, F. von Koch, U. Conrad, W. Fett, C. Kurzeder, H. J. Lück, E. Stickeler, H. Urbaczyk, B. Liedtke, C. Salat, N. Harbeck, V. Müller, M. Schmidt, S. Hasmüller, M. Lenhard, T. Schuster, V. Nekljudova, A. Lebeau, S. Loibl, G. von Minckwitz, on behalf of the Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators
Annals of Oncology, Vol. 22, No. 9. (01 September 2011), pp. 1988-1998, doi:10.1093/annonc/mdq709 Key: citeulike:9761846
Formatted Citation
Show HTML
Likes (beta)
This copy of the article hasn't been liked by anyone yet.
View FullText article
Abstract
Background: Preoperative chemotherapy is a recommended treatment of both primary operable and locally advanced breast cancer. Strategies to improve efficacy include the use of anthracyclines, taxanes, and intensified dose with bone marrow support.
eraderna's tags for this article
Citations (CiTO)
No CiTO relationships defined
There are no reviews yet
